Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$10.91 USD
-0.28 (-2.50%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $10.90 -0.01 (-0.09%) 5:12 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.91 USD
-0.28 (-2.50%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $10.90 -0.01 (-0.09%) 5:12 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Dynavax Technologies (DVAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.
Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 19.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Dynavax Technologies (DVAX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.
Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.
Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.
ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.
Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright
by Zacks Equity Research
Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.
Has Dynavax Technologies (DVAX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVAX) Outperforming Other Medical Stocks This Year?
Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.
Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.